nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

21.11.2020 | Review

The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

verfasst von: Chongzhen Guo, Chengda Yan, Lianyue Qu, Rongrong Du, Jianyang Lin

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the efficacy and toxicity of angiogenesis inhibitors for the treatment of ovarian cancer patients, we conducted a meta-analysis of the published literature on this subject.

Methods

In this meta-analysis, we searched PubMed, EMBASE, Web of Science, and Cochrane Library databases for randomized controlled trials (RCTs). The literature search was performed up to August 12, 2019. The risk of bias of the included studies was evaluated using The Cochrane Collaboration's tool, and the statistical analyses were performed using RevMan 5.3 software. The sensitivity analysis was performed with Stata 12.0 software.

Results

22 RCTs with 11,254 patients were included. Our meta-analysis demonstrates that angiogenesis inhibitors therapy can significantly improve progression-free survival (PFS) (hazard ratio [HR] 0.71, 95% CI 0.63–0.79, I² = 80%, P < 0.00001) and overall survival (OS) (HR 0.95, 95% CI 0.90–0.99, I² = 0%, P = 0.03) in ovarian cancer patients. The subgroups results suggest differences in the benefit in OS in first-line treatment (HR 1.00, 95% CI 0.93–1.08, I² = 0%, P = 0.90) compared with treatment at relapse (HR 0.87, 95% CI 0.81–0.95, I² = 0%, P = 0.0008). The PFS improved both in first-line treatment (HR 0.87, 95% CI 0.79–0.95, I² = 60%, P = 0.003) and recurrent treatment (HR 0.60, 95% CI 0.53–0.67, I² = 57% P < 0.0001) patients. The PFS and OS in recurrent group were prolonged both in the platinum-resistant group(PFS: HR 0.50, 95% CI 0.42–0.60, I² = 0%, P < 0.00001; OS: HR 0.76, 95% CI 0.62–0.93, I² = 0%, P = 0.007) and the platinum-sensitive group (PFS: HR 0.58, 95% CI 0.49–0.69, I² = 64%, P < 0.00001; OS: HR 0.88, 95% CI 0.79–0.99, I² = 0%, P = 0.03). However, this therapy is associated with a higher risk of common adverse events of grade ≥ 3 (risk ratio [RR]: 1.12; 95% CI 1.07–1.17; I² = 0%, P = 0.68) such as arterial thromboembolic disease, ascites, diarrhea, gastrointestinal perforations, headache, hemorrhagic, hypertension, hypokalemia, leucopenia, pain, proteinuria, thrombocytopenia, and thrombosis or embolism.

Conclusion

This meta-analysis suggests angiogenesis inhibitors may significantly improve PFS and OS of ovarian cancer patients and increase the incidence of common adverse events.

Siegel Rebecca L, Miller Kimberly D (2020) Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Luvero D, Milani A, Ledermann JA (2014) Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 6(5):229–239. https://doi.org/10.1177/1758834014544121CrossRefPubMedPubMedCentral

Jászai J, Schmidt MHH (2019) Trends and challenges in tumor anti-angiogenic therapies. Cells 8(9):1102. https://doi.org/10.3390/cells8091102CrossRefPubMedCentral

Abdalla AME, Xiao L, Ullah MW, Yu M, Ouyang C, Yang G (2018) Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics. Theranostics 8(2):533–548. https://doi.org/10.7150/thno.21674CrossRefPubMedPubMedCentral

Teleanu RI, Chircov C, Grumezescu AM, Teleanu DM (2019) Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. J Clin Med 9(1):84. https://doi.org/10.3390/jcm9010084CrossRefPubMedCentral

Saman H, Raza SS, Uddin S, Rasul K (2020) Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches. Cancers (Basel) 12(5):E1172. https://doi.org/10.3390/cancers12051172CrossRef

Higgins JP, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928CrossRefPubMedPubMedCentral

Pignata S, Lorusso D, Joly F et al (2018) Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol. https://doi.org/10.1200/JCO.2018.36.15_suppl.5506CrossRefPubMedPubMedCentral

10.

Ledermann JA, Embleton AC, Perren T et al (2017) Overall survival results of ICON6: a trial of chemotherapy and cediranib in relapsed ovarian cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2017.35.15_suppl.5506CrossRef

11.

Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV (2015) Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 139(1):10–16. https://doi.org/10.1016/j.ygyno.2015.08.004CrossRefPubMedPubMedCentral

12.

Gotlieb WH, Amant F, Advani S et al (2012) Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 13(2):154–162. https://doi.org/10.1016/S1470-2045(11)70338-2CrossRefPubMed

13.

Karlan BY, Oza AM, Richardson GE et al (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4):362–371. https://doi.org/10.1200/JCO.2010.34.3178CrossRefPubMed

14.

Elice F, Rodeghiero F (2010) Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res 125(Suppl 2):S55–S57. https://doi.org/10.1016/S0049-3848(10)70014-1CrossRefPubMed

15.

Jiang Y, Sun X, Kong B, Jiang J (2018) Antiangiogenesis therapy in ovarian cancer patients: an updated meta-analysis for 15 randomized controlled trials. Medicine (Baltimore) 97(34):e11920. https://doi.org/10.1097/MD.0000000000011920CrossRef

16.

Vergote IB, Jimeno A, Joly F et al (2014) Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol 32(4):320–326. https://doi.org/10.1200/JCO.2013.50.5669CrossRefPubMed

17.

Colombo N, Sessa C, du Bois A et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 30(5):672–705. https://doi.org/10.1093/annonc/mdz062CrossRefPubMed

18.

Vergote I, Hanker LC, Floquet A et al (2018) AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results. J Clin Oncol. https://doi.org/10.1200/JCO.2018.36.15_suppl.5518CrossRef

19.

Cook SA, Tinker AV (2019) PARP inhibitors and the evolving landscape of ovarian cancer management: a review. BioDrugs 33(3):255–273. https://doi.org/10.1007/s40259-019-00347-4CrossRefPubMed

20.

Liu JF, Barry WT, Birrer M et al (2019) Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 30(4):551–557. https://doi.org/10.1093/annonc/mdz018CrossRefPubMedPubMedCentral

21.

Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416–2428. https://doi.org/10.1056/NEJMoa1911361CrossRefPubMed

22.

Jayson GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388(10043):518–529. https://doi.org/10.1016/S0140-6736(15)01088-0CrossRefPubMed

23.

Bais C, Mueller B, Brady MF et al (2017) Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx066CrossRefPubMedPubMedCentral

24.

Secord AA, Burdett KB, Owzar K et al (2020) Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: results from GOG-0218. Clin Cancer Res 26(6):1288–1296. https://doi.org/10.1158/1078-0432.CCR-19-0226CrossRefPubMedCentral

25.

Friedlander M, Rau J, Lee CK et al (2018) Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy. Ann Oncol 29(3):737–743. https://doi.org/10.1093/annonc/mdx796CrossRefPubMed

26.

Stark D, Nankivell M, Pujade-Lauraine E et al (2013) Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14(3):236–243. https://doi.org/10.1016/S1470-2045(12)70567-3CrossRefPubMedPubMedCentral

27.

Gore M, Hackshaw A, Brady WE et al (2019) An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol 153(3):541–548. https://doi.org/10.1016/j.ygyno.2019.03.256CrossRefPubMedPubMedCentral

28.

Tewari KS, Burger RA, Enserro D et al (2019) Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37(26):2317–2328. https://doi.org/10.1200/JCO.19.01009CrossRefPubMedPubMedCentral

29.

Coleman RL, Brady MF, Herzog TJ et al (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18(6):779–791. https://doi.org/10.1016/S1470-2045(17)30279-6CrossRefPubMedPubMedCentral

30.

Oza AM, Cook AD, Pfisterer J et al (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16(8):928–936. https://doi.org/10.1016/S1470-2045(15)00086-8CrossRefPubMedPubMedCentral

31.

Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302–1308. https://doi.org/10.1200/JCO.2013.51.4489CrossRefPubMed

32.

Kim JW, Mahner S, Wu LY et al (2018) Pazopanib maintenance therapy in east Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer 28(1):2–10. https://doi.org/10.1097/IGC.0000000000000602CrossRefPubMed

33.

Richardson DL, Sill MW, Coleman RL et al (2018) Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol 4(2):196–202. https://doi.org/10.1001/jamaoncol.2017.4218CrossRefPubMed

34.

Pignata S, Lorusso D, Scambia G et al (2015) Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol 16(5):561–568. https://doi.org/10.1016/S1470-2045(15)70115-4CrossRefPubMed

35.

Ray-Coquard I, Cibula D, Mirza MR et al (2020) Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer 146(2):439–448. https://doi.org/10.1002/ijc.32606CrossRefPubMed

36.

Ledermann JA, Hackshaw A, Kaye S et al (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29(28):3798–3804. https://doi.org/10.1200/JCO.2010.33.5208CrossRefPubMed

37.

Chekerov R, Hilpert F, Mahner S et al (2018) Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 19(9):1247–1258. https://doi.org/10.1016/S1470-2045(18)30372-3CrossRefPubMed

38.

Herzog TJ, Scambia G, Kim BG et al (2013) A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol 130(1):25–30. https://doi.org/10.1016/j.ygyno.2013.04.011CrossRefPubMed

39.

Vergote I, Scambia G, O’Malley DM et al (2019) Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol 20(6):862–876. https://doi.org/10.1016/S1470-2045(19)30178-0CrossRefPubMed

40.

Marth C, Vergote I, Scambia G et al (2017) ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer 70:111–121. https://doi.org/10.1016/j.ejca.2016.09.004CrossRefPubMed

41.

Monk BJ, Poveda A, Vergote I et al (2016) Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol 143(1):27–34. https://doi.org/10.1016/j.ygyno.2016.07.112CrossRefPubMed

Titel: The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials
verfasst von: Chongzhen Guo
Chengda Yan
Lianyue Qu
Rongrong Du
Jianyang Lin
Publikationsdatum: 21.11.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2021
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-020-05865-z

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Clinical characteristics and risk factors of invasion in extramammary Paget’s disease of the vulva

Risk factors for massive hemorrhage during the treatment of cesarean scar pregnancy: a systematic review and meta-analysis

Severe cervical inflammation and high-grade squamous intraepithelial lesions: a cross-sectional study

Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial

Development and psychometric evaluation of the Sexual Health Assessment Tool for Infertile Women (SEHAT-IW)

Comparing prophylactic use of cefazolin for SSI in cesarean section: a systematic review and meta-analysis

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

Fehlerkultur in der Medizin – Offenheit zählt!

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

Update Gynäkologie